ANI Pharmaceuticals (ANIP) PT Bumped to $70 at Roth Capital

Roth Capital analyst Scott Henry bumped his price target on Neutral-rated ANI Pharmaceuticals (NASDAQ: ANIP) to $70.00 (from $60.00), saying Teva deal #2 is a positive.

Henry commented, "ANIP recently completed a second Teva deal to acquire 22 previously approved generic products for $25 million in cash. We view this deal positively with potential to drive revenues in 2H16 and beyond. Our price target increase to $70/share reflects this event. Maintain Neutral rating as we would wait for pullbacks to be more aggressive with shares."

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $67.53 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• Edison International (EIX) PT Lowered to $63 at UBS
• Kazia Therapeutics (KZIA) PT Raised to $40 at BTIG